American International Group, Inc. Rallybio Corp Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.25 - $2.4 $162 - $312	-130 Reduced 0.86%	15,067 $27,000
Q4 2023 Feb 13, 2024	SELL	$1.91 - $4.39 $116 - $267	-61 Reduced 0.4%	15,197 $36,000
Q3 2023 Nov 13, 2023	BUY	$3.37 - $6.16 $1,829 - $3,344	543 Added 3.69%	15,258 $51,000
Q2 2023 Aug 04, 2023	BUY	$4.31 - $8.89 $24,282 - $50,086	5,634 Added 62.04%	14,715 $83,000
Q1 2023 May 12, 2023	BUY	$4.37 - $8.75 $1,616 - $3,237	370 Added 4.25%	9,081 $51,000
Q4 2022 Feb 10, 2023	BUY	$4.67 - $14.86 $5,309 - $16,895	1,137 Added 15.01%	8,711 $57,000
Q3 2022 Nov 14, 2022	BUY	$7.54 - $14.56 $814 - $1,572	108 Added 1.45%	7,574 $110,000
Q2 2022 Aug 12, 2022	SELL	$6.26 - $13.65 $9,502 - $20,720	-1,518 Reduced 16.9%	7,466 $56,000
Q1 2022 May 13, 2022	BUY	$6.91 - $15.04 $35,655 - $77,606	5,160 Added 134.94%	8,984 $63,000
Q4 2021 Feb 11, 2022	SELL	$9.3 - $19.91 $1,069 - $2,289	-115 Reduced 2.92%	3,824 $36,000
Q3 2021 Nov 12, 2021	BUY	$10.83 - $23.4 $42,659 - $92,172	3,939 New	3,939 $69,000

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $30.5M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.